Simple, convenient dosing with once-daily oral Fruzaqla

In FRESCO-2, the majority of adverse events (AEs) with Fruzaqla were manageable and predictable^1-3

FRESCO-2 was a global, randomized, double-blind, multicenter phase 3 study, evaluating the efficacy and safety of Fruzaqla + best supportive care (BSC) vs. Placebo + BSC.^1,2

Fruzaqla is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipira

Pooled data from EMPOWER/ENABLE shed light on outcomes in adolescents with Hereditary
Angioedema (HAE). The study reports the effectiveness and safety of TAKHZYRO in preventing
attacks in patients aged 12–18 years with HAE-C1INH.

Discover in this video how modern long-term prophylaxis is transforming the treatment of
Hereditary Angioedema (HAE), improving clinical outcomes and quality of life.

for you and your patients

Le Conseil Supérieur de la Santé recommande la (lis)dexamphétamine ou le méthylphenidate comme alternatives équivalentes au traitement médicamenteux de premier choix chez les adultes avec TDAH, parmi lesquelles les préparations à action prolongée sont préférées.¹

Episode 1 Description: In this episode, experts and patients share their perspectives on the medical and emotional journey of transplant patients, with a focus on maintaining and improving quality of life (QoL).